Drugs / FOSDESDENOSINE SIPALABENAMIDE
FOSDESDENOSINE SIPALABENAMIDE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03829254 | Jun 2019 → Aug 2026 overdue | lymphoma, melanoma | NuCana plc | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 14
| Date | Issuer | Release |
|---|---|---|
| 2026-05-14 | Nucana | Regulatory NuCana Reports First Quarter 2026 Financial Results and Provides Business Update nucana.com ↗
We are also delighted to announce that the U.S. Food and Drug Administration (the “FDA”) cleared our Investigational New Drug application (“IND”) for NUC-7738 in April 2026. |
| 2025-12-10 | Nucana | Results NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma nucana.com ↗
Clinical activity includes two partial responses (one confirmed) and seven cases of stable disease, notably including one ongoing stable disease converting to a complete metabolic response with no detectable active disease. |
| 2025-10-18 | Nucana | Results NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress 2025 nucana.com ↗
Using patient-derived organoids (“PDOs”) from ten patients with RCC and autologous tumor-infiltrating lymphocytes (“TILs”), co-culture experiments reveal that NUC-7738 enhances the effectiveness of PD-1 inhibitors, resulting in increased tumor cell killing. |
| 2024-09-14 | Nucana | Results NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024 nucana.com ↗ |
| 2024-05-16 | Nucana | Results NuCana Reports First Quarter 2024 Financial Results and Provides Business Update nucana.com ↗
NUC-7738 plus Pembrolizumab Demonstrated Encouraging Anti-Cancer Activity in Several Patients who were Resistant to PD-1 Inhibitors |
| 2024-04-09 | Nucana | Results NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study nucana.com ↗
NUC-7738 was found to increase polyunsaturated fatty acids within the TME, which is indicative of a shift to a less aggressive cancer type and to decrease monounsaturated fatty acids which are associated with malignant behavior and chemotherapy resistance. |
| 2023-10-16 | Nucana | Results NuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 nucana.com ↗
Encouraging signs of efficacy, including tumor volume reductions and prolonged time on treatment have been observed in both the monotherapy and combination cohorts. |
| 2023-04-14 | Nucana | Results NuCana Presents Data at the AACR 2023 Annual Meeting Highlighting Novel NUC-7738 Mechanisms of Action nucana.com ↗
Data from this study demonstrate that NUC-7738 reduced mRNA and protein levels of soluble PD-L1 in a melanoma cell line and that patients treated with NUC-7738 had reduced levels of exosomal PD-L1 compared to pre-treatment levels. |
| 2022-09-12 | Nucana | Results NuCana Presents Promising Data on NUC-7738 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022 nucana.com ↗
Data on NUC-7738 from the Phase 1 part of NuTide:701 showed encouraging signals of anti-tumor activity across a range of tumor types, particularly melanoma. |
| 2022-06-10 | Nucana | Results NuCana Announces Presentation on NUC-7738 at the European Hematology Association (EHA) 2022 Hybrid Congress nucana.com ↗
The data at EHA 2022 show that NUC-7738 can suppress the expansion and survival of AML cells by reducing β-catenin signaling, a key pathway in AML. |
| 2021-09-16 | Nucana | Results NuCana Announces Four Poster Presentations at the ESMO Congress 2021 nucana.com ↗
Three case studies were described detailing two patients with metastatic melanoma and one patient with metastatic lung adenocarcinoma who achieved reductions in the size of target lesions coupled with prolonged stable disease. |
| 2021-04-10 | Nucana | Results NuCana Announces Five Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021 nucana.com ↗
NUC-7738 Demonstrates Anti-Cancer Activity, Prolonged Stable Disease and a Favorable Tolerability Profile in Patients with Advanced Solid Tumors |
| 2020-09-21 | Nucana | Results NuCana Presents Three Posters at the ESMO Virtual Congress 2020 nucana.com ↗ |
| 2019-10-29 | Nucana | Results NuCana Presents Data at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics nucana.com ↗
In non-clinical studies of NUC-7738, NuCana has observed additional anti-cancer mechanisms of action to those previously reported for 3’dA. |
All press releases naming this drug 18 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FOSDESDENOSINE SIPALABENAMIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5277528 ↗ |
| Known as | Fosdesdenosina sipalabenamida | ChEMBL registry synonym — accepted as the source's own label CHEMBL5277528 ↗ |
| Known as | NUC-7738 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03829254 ↗ |
| Modality | Small molecule | — CHEMBL5277528 ↗ |
| Route | Intravenous | “NUC-7738 administered by intravenous infusion” NCT03829254 ↗ |